<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="410">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02043665</url>
  </required_header>
  <id_info>
    <org_study_id>VLA 009/ KEYNOTE-200</org_study_id>
    <secondary_id>2012-005256-42</secondary_id>
    <nct_id>NCT02043665</nct_id>
  </id_info>
  <brief_title>Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200)</brief_title>
  <official_title>A Phase 1, Dose-finding and Signal-seeking Study of the Safety and Efficacy of Intravenous CAVATAK™ (Coxsackievirus A21, CVA21) Alone and in Combination With Cytotoxic Chemotherapy in Patients With Late Stage Solid Tumours (NSCLC, Castrate-resistant Prostate Cancer, Melanoma, Bladder Cancer).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viralytics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Viralytics</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to assess the ability of CVA21, either alone (Part A) or in
      combination with pembrolizumab (Part B), to reach and to replicate in existing tumors (while
      sparing normal cells) and to establish a safe multi-dose schedule of the virus for the
      treatment of solid tumors where enhanced experssion of ICAM-1 and/ or DAF receptor occurs.

      This trial will consist of 2 sequential parts: VLA-009 (Part A) conducted only in the UK
      employs CVA21 as a monotherapy in NSCLC, castrate-resistant prostate cancer, melanoma and
      bladder cancer. VLA-009 (Part B) conducted in the US and UK employs CVA21 with pembrolizumab
      in NSCLC and bladder cancer.

      Both VLA-009A and VLA-009B are open-label, multi-center, ascending dose escalation (3+3
      design) dose-finding and signal-seeking studies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Response rate assessed according to immune-related RECIST 1.1 criteria</measure>
    <time_frame>Up to 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Castrate-resistant Prostate Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>VLA 009A (First stage), VLA 009B (Second stage)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CVA21</intervention_name>
    <arm_group_label>VLA 009A (First stage), VLA 009B (Second stage)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically-confirmed (1) NSCLC, (2) bladder cancer, (3) castrate-resistant
             prostate cancer which are metastatic, or (4) stage 3C or stage 4 melanoma.

          -  VLA009A: Locally advanced and/or metastatic disease for which curative surgery and/or
             radiation therapy is not possible and judged not to be a candidate for the current
             standard of care treatment. VLA009B: locally advanced and/or metastatic disease and
             judged to be a candidate for the selected cytotoxic therapy to be used in combination
             with CVA21.

          -  All subjects in Cohort 3 or Phase 2 dose (P2D) must have a lesion accessible for FNA
             or core or open biopsy on day 8 of the first treatment cycle.

          -  No CVA21 neutralising antibody (≤ 1:16)

          -  Measurable or evaluable disease

        Exclusion Criteria:

          -  Second primary malignancy within the past 2 years (except non-melanoma skin cancer,
             in situ carcinoma of the cervix, breast cancer)

          -  Concurrent immunosuppressive therapy and no known immunosuppressive disease other
             than primary tumour

          -  VLA009B: no medical contraindications to planned cytotoxic therapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hardev Pandha</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Surrey County Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Guttman</last_name>
    <email>Lisa.Guttman@viralytics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brendan Curti, MD</last_name>
      <email>brendan.curti@providence.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St James University Hospital</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christy Ralph</last_name>
    </contact>
    <contact_backup>
      <last_name>Jennifer Boards</last_name>
      <phone>+44 (0)113 206797</phone>
      <email>Jennifer.Boards@leedsth.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Christy Ralph</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Cancer Research</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Harrington</last_name>
    </contact>
    <contact_backup>
      <last_name>Rachel Starkings</last_name>
      <phone>+44 (0)207 8082516</phone>
      <email>Rachel.Starkings@rmh.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Kevin Harrington</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Surrey</name>
      <address>
        <city>Surrey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hardev Pandha</last_name>
    </contact>
    <contact_backup>
      <last_name>Wendy Hobby</last_name>
      <phone>+44 (0)1483 688602</phone>
      <email>w.hobby@surrey.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Hardev Pandha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 12, 2016</lastchanged_date>
  <firstreceived_date>January 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAVATAK</keyword>
  <keyword>KEYNOTE-200</keyword>
  <keyword>pembrolizumab</keyword>
  <keyword>lung cancer</keyword>
  <keyword>bladder cancer</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
